Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Dow
McKesson
Boehringer Ingelheim
Express Scripts

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Arbekacin

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Arbekacin?

Arbekacin is an investigational drug.

There have been 5 clinical trials for Arbekacin. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2013.

The most common disease conditions in clinical trials are Infection, Communicable Diseases, and Pneumonia, Bacterial. The leading clinical trial sponsors are Meiji Seika Pharma Co., Ltd., Uniformed Services University of the Health Sciences, and Kobe University.

There are seven hundred and ten US patents protecting this investigational drug and five international patents.

Recent Clinical Trials for Arbekacin
TitleSponsorPhase
A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial PneumoniaMeiji Seika Pharma Co., Ltd.Phase 1
Intrapulmonary Pharmacokinetics of ME1100 in Healthy VolunteersMeiji Seika Pharma Co., Ltd.Phase 1
Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular DystrophyJapan Medical AssociationPhase 2

See all Arbekacin clinical trials

Clinical Trial Summary for Arbekacin

Top disease conditions for Arbekacin
Top clinical trial sponsors for Arbekacin

See all Arbekacin clinical trials

US Patents for Arbekacin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Arbekacin   Start Trial Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
Arbekacin   Start Trial Anti-CS1 antibodies and antibody drug conjugates AbbVie Biotherapeutics Inc. (Redwood City, CA)   Start Trial
Arbekacin   Start Trial Composition including rapamycin as active ingredient for preventing or treating hearing loss AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (Suwon-si, Gyeonggi-do, KR)   Start Trial
Arbekacin   Start Trial Nucleic acid vaccines ModernaTX, Inc. (Cambridge, MA)   Start Trial
Arbekacin   Start Trial Polynucleotides encoding immune modulating polypeptides ModernaTX, Inc. (Cambridge, MA)   Start Trial
Arbekacin   Start Trial Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same Laboratory Skin Care, Inc. (Redwood City, CA)   Start Trial
Arbekacin   Start Trial Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life The Regents of the University of California (Oakland, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Arbekacin

Drugname Country Document Number Estimated Expiration Related US Patent
Arbekacin Australia 2011210567 2030-01-29   Start Trial
Arbekacin Canada 2787784 2030-01-29   Start Trial
Arbekacin European Patent Office 2528893 2030-01-29   Start Trial
Arbekacin European Patent Office 3138838 2030-01-29   Start Trial
Arbekacin Japan 2013518816 2030-01-29   Start Trial
Arbekacin Japan 2016183175 2030-01-29   Start Trial
Arbekacin Japan 5937968 2030-01-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
AstraZeneca
Harvard Business School
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.